ClinicaliQ Trial Snapshot
- Study of Daraxonrasib and Daraxonrasib + GnP as First-line Treatment in Patients With Metastatic Pancreatic Adenocarcinoma — Recruiting • Phase III • Oncology • NCT07491445.
- What is being tested: Daraxonrasib, a novel RAS(ON) inhibitor, evaluated both as monotherapy and in combination with gemcitabine/nab-paclitaxel (GnP) chemotherapy versus standard chemotherapy alone in treatment-Phase IIIïve metastatic pancreatic adenocarcinoma.
- Patient eligibility overview: Adults with newly diagnosed metastatic pancreatic adenocarcinoma without prior systemic therapy, with adequate organ function and performance status suitable for first-line chemotherapy.
Use This Page For
- Quick orientation before opening the registry record.
- Checking recruitment status, phase and sponsor at a glance.
- Connecting this trial to nearby guidelines, Drug Science and education.
What This Trial Is Studying
The purpose of this study is to evaluate the safety and efficacy of an investigational RAS(ON) inhibitor administered as monotherapy or in combination with chemotherapy, compared with standard of care (SOC) chemotherapy alone.
Eligibility Snapshot
- : * At least 18 years old and has provided informed consent. * Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1. * Histologically or cytologically confirmed pancreatic adenocarcinoma. * Diagnosis of metastatic disease ≤ 6 weeks prior to informed consent. * Documented RAS mutation status, either mutant or wild-type. * Measurable disease per RECIST v1.1. * Adequate organ function (bone marrow, liver, kidney, coagulation). * Able to take oral medications.
Use the source registry for the full inclusion and exclusion criteria before discussing referral or enrolment.